10-Q quarterly report · filed Oct 8, 2026

ANGIODYNAMICS INC (ANGO) Q3 2026 10-Q Quarterly Report

Short answer

ANGIODYNAMICS INC (ANGO) filed its Q3 2026 10-Q quarterly report on Oct 8, 2026 for the quarter ended Aug 31, 2026. Quarterly revenue was $81M (up 6.9% year over year) with net income of −$7M.

Q3 2026 key financials · XBRL

Revenue
$81M
+6.9% YoY
Net income
−$7M
+34.9% YoY
Operating margin
-9.0%
Gross margin
59.4%
EPS (diluted)
−$0.17
+34.6% YoY

Source: XBRL data from the ANGIODYNAMICS INC (ANGO) Q3 2026 10-Q on SEC EDGAR. USD.

ANGIODYNAMICS INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $80.9M, up $5.2M or 6.9% YoY from $75.7M
  • Gross margin 59.4% vs 55.3% YoY, Med Tech margin 66.2% vs 62.2%
  • Med Tech strongest, revenue up 13.2% to $39.9M; Med Device weakest, up 1.4% to $41.0M
  • Cash $34.0M vs $53.9M at May 31; operating cash use $15.3M, Auryon placements $2.8M
  • Headwinds: inflation, tariffs, labor shortages, supply-chain challenges, backlog; liquidity sufficient for at least 12 months

Risk Factors

  • No material changes to fiscal 2026 10-K risk factors
  • Legal risk: approximately [number obscured] port product-liability claims remain pending
  • Regulatory risk: FDA actions or changing medical-device regulations could delay product clearances or approvals
  • Operational risk: manufacturing, supply-chain, labor, inflation and tariff pressures could disrupt production and margins
  • Financial risk: cash declined to $34.0 million after $15.3 million operating cash outflow; no revolving debt outstanding
  • Currency risk: 2.3% of sales denominated in foreign currencies, with no comparable foreign-currency expenses

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ANGIODYNAMICS INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.